Fatigue that persists for 6 months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Inflammation, immune system activation, autonomic dysfunction, impaired functioning in the hypothalamicpituitary-adrenal axis, and neuroendocrine dysregulation have all been suggested as root causes of fatigue. The identification of objective markers consistently associated with CFS/ME is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. This review is focused on the recent literature related to biomarkers for fatigue associated with CFS/ME and, for comparison, those associated with other diseases. These markers are distributed across several of the body's core regulatory systems. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine and immune systems. We propose that new insight will depend on our ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level. Until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.
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Background
Fatigue is a common symptom that includes both physical and mental components. It can be an acute response to physical, mental or infectious triggers and usually decreases as the trigger recedes. It can occur in healthy people as a result of physical and/or mental exertion. Symptoms of fatigue persisting for 6 months or more define chronic fatigue (CF). A survey of 2323 residents of Norway by Loge et al. (1998) reported CF to be endorsed by 11% of the general population. Of those respondents reporting no known disease or current heath problem, 7% had CF. In contrast, in Japan, more than half of the general adult population complained of fatigue, and more than one third of the population endorsed CF (Watanabe et al., 2008) .
Disease associated fatigue may be directly related to the disease mechanisms (primary fatigue) or may be secondary to non-disease-specific factors. Measurement of fatigue can be from either the subjective or the objective standpoint and includes physical fatigue, reduced motivation, reduced activity, and mental fatigue. The magnitude and scope of debilitating fatigue is a central component in health care where chronic illness is a growing concern. Current acute illness research models are inadequate for resolving chronic disorders affecting multiple regulatory systems and presenting with complex constellations of symptoms. Fatigue is a fundamental component in a diverse array of illnesses that affect a broad patient demographic.
There is a growing body of research directed toward understanding the biology of fatigue; this research leads us to regard fatigue as a complex construct of symptoms that emerges from alteration and/or dysfunction in the nervous, endocrine and immune systems. Identifying biomarkers of CF is an important part of this effort. The official NIH definition of a biomarker is: ''a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.'' (Biomarkers Definitions Working Group, 2001) . In this review of recent work, we selected examples of research on CF occurring in disease with an emphasis on chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). The biomarker research examined included several levels of biology ranging from the intracellular (transcript) to the intercellular (cytokine and hormone) and behavioral levels (clinical and psychometric measures). Our aim in the selection of studies was not to be inclusive, but rather to include a representative 
